

Pertuzumab APHINITY

Pertuzumab APHINITY

PRELIMINARY SCORE

SCORE

CURATIVE

CURATIVE

NEB

NEB

NON-CURATIVE

NON-CURATIVE

ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Overall Survival / Disease-Free Survival / Pathological Complete Response

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (node-positive or hormone receptor-negative disease)

Experimental Arm: Pertuzumab + Standard adjuvant ChT + 1 year of treatment with trastuzumab

Control Arm: Placebo + standard adjuvant ChT + 1 year of treatment with trastuzumab



